Multi-month discounts are real, and so is the fact that compounded medication is generally not refundable once shipped.
Most programs discount heavily for prepaying three, six or twelve months. The saving is genuine — often $30 to $60 a month — and so is the exposure, because compounded medication is generally not refundable once it has shipped.
The pattern in complaints is consistent: a patient prepays during titration, does not tolerate the drug, and discovers the term is not refundable. Prepaying before you know you tolerate a maintenance dose puts money at risk against the single most likely reason to stop.
The sequencing that protects you is simple. Monthly billing until you have held a maintenance dose for a cycle; prepaid after, when the main reason to stop has already passed.
Two questions before committing: does the discounted rate hold for the whole term or revert at renewal, and what happens if a clinician stops your prescription mid-term. Both answers should be in writing.
Sources
- Provider terms of service and published plan pricing, 2026
Dated 2026-02-10. If this item is out of date or wrong, tell us through contact and the change is logged in corrections.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.